IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the...

Area of Science:

• Urology
• Oncology
• Biomarker Development

Background:

• Prostate cancer diagnosis often involves PSA testing.
• Medications for benign prostatic hyperplasia, such as 5-alpha reductase inhibitors (5-ARI) and alpha-blockers, can affect PSA levels.
• Evaluating diagnostic markers in patients using these medications is crucial.

Purpose of the Study:

• To assess the impact of 5-alpha reductase inhibitors (5-ARI) and alpha-blockers on the performance of IsoPSA.
• To determine if IsoPSA can reliably detect actionable prostate cancer in men taking these common medications.

Main Methods:

• Secondary analysis of a prospective, multicenter study involving 888 men aged 50+ with PSA ≥ 4 ng/mL.
• Patients were grouped based on the use of 5-ARI and/or alpha-blockers.
• Performance characteristics (sensitivity, specificity, ROC analysis) of IsoPSA were evaluated across these groups.

Main Results:

• IsoPSA sensitivity for detecting prostate cancer and actionable cancer was similar between patient subsets.
• Specificity was unaffected by 5-ARI use but showed a significant increase in patients taking alpha-blockers.
• ROC analysis confirmed IsoPSA performance is unaffected by 5-ARI or alpha-blocker use for detecting prostate cancer (GG2+).

Conclusions:

• IsoPSA demonstrates robust performance in detecting prostate cancer and actionable prostate cancer.
• The diagnostic accuracy of IsoPSA is not compromised by the use of 5-ARI or alpha-blockers.
• IsoPSA is a reliable tool for prostate cancer detection, even in men with benign prostatic hyperplasia symptoms.